A clinical benefit full of life
POLIVY-R-CHP: the first clinically meaningful improvement over a standard of care that held for 20 years1-13
Watch Expert Perspectives
Specialist views covering a range of POLARIX trial topics
![watch-expert-perspectives-image1.png](https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image1.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image1.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image1.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
Dr Hervé Tilly,
University of Rouen, France
![watch-expert-perspectives-image2.png](https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image2.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image2.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image2.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
Prof. Christopher Flowers,
MD, Anderson Cancer Center, University of Texas
![watch-expert-perspectives-image3.png](https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image3.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image3.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image3.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
Dr Franck Morschhauser,
MD, PhD Professor of Hematology,
University of Lille
![watch-expert-perspectives-image4.png](https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image4.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image4.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/watch-expert-perspectives-image4.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
Dr Laurie H. Sehn,
MD, MPH Clinical Assistant
Professor with the BC Cancer Agency and University
of British Columbia
![27-percent-min.png](https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/27-percent-min.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/27-percent-min.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/27-percent-min.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
reduced risk of progression, relapse, or death with
POLIVY-R-CHP vs R-CHOP.1,*
That means more hope for the future, and more freedom from the threat of disease.
![quote-icon.png](https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/icons/quote-icon.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/icons/quote-icon.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/icons/quote-icon.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
“The new regimen should reduce the risk of relapse and help patients avoid intensive treatments such as stem cell transplantation and chimeric antigen receptor T-cell therapy.”14
– Dr Gilles Salles, MD, PhD
Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center
![Group9906@2x.png](https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/Group9906@2x.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/Group9906@2x.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/polivy/en/images/Group9906@2x.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
About POLIVY
Considering using
POLIVY-R-CHP for your patients?
Learn more about dosage, administration, and mechanism of action
*Stratified hazard ratio 0.73; 95% CI, 0.57–0.95; P=0.021
1L=first line; DLBCL=diffuse large B-cell lymphoma; POLIVY-R-CHP=polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, prednisone; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone.
References:
- Tilly H, et al. N Engl J Med. 2022;386:351-63.
- Aurer I, et al. Eur J Haematol. 2011;86:111-6.
- Bartlett NL, et al. J Clin Oncol. 2019;37:1790-9.
- Coiffier B, et al. N Engl J Med. 2002;346:235-42.
- Cunningham D, et al. Lancet. 2013;381:1817-26.
- Davies A, et al. Lancet Oncol. 2019;20:649-62.
- Iacoboni G, et al. Ann Oncol. 2018;29:1120-9.
- Jaeger U, et al. Haematologica. 2015;100:955-63.
- Seymour JF, et al. Haematologica. 2014;99:1343-9.
- Vitolo U, et al. J Clin Oncol. 2017;35:3529-37.
- Vitolo U, et al. Hematol Oncol. 2019;37:36-7.
- Witzig TE, et al. Ann Oncol. 2018;29:707-14.
- Younes A, et al. J Clin Oncol. 2019;37:1285-95.
- ASCO Post. 2021 [cited 2022 15 July]. Available from: https://ascopost.com/news/december-2021/polarix-pola-r-chp-vs-r-chop-for-previously-untreated-patients-with-dlbcl/.